Fidelity Select Pharmaceuticals Portfolio FPHAX

Medalist Rating as of | See Fidelity Investment Hub
  • NAV / 1-Day Return 33.86  /  −0.18 %
  • Total Assets 1.6B
  • Adj. Expense Ratio
    0.670%
  • Expense Ratio 0.670%
  • Distribution Fee Level Low
  • Share Class Type No Load
  • Category Health
  • Investment Style Large Blend
  • Min. Initial Investment 0
  • Status Open
  • TTM Yield 2.55%
  • Turnover 77%

USD | NAV as of Oct 03, 2026 | 1-Day Return as of Oct 03, 2026, 12:11 AM GMT+0

Morningstar’s Analysis FPHAX

Will FPHAX outperform in the future?

Get our overall rating based on a fundamental assessment of the pillars below.

null Morningstar Automated Analysis

Morningstar Automated Analysis

Summary

Fidelity Select Pharmaceuticals Port holds a quantitatively derived Gold Morningstar Medalist Rating. The rating reflects that it has scored particularly well on factors Morningstar research associates with future outperformance relative to category peers.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings FPHAX

  • Current Portfolio Date
  • Equity Holdings —
  • Bond Holdings —
  • Other Holdings —
  • % Assets in Top 10 Holdings 72.1
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Eli Lilly and Co

24.47 400M
Healthcare

GSK PLC ADR

7.92 129M
Healthcare

Merck & Co Inc

6.37 104M
Healthcare

Viatris Inc

5.46 89M
Healthcare

AstraZeneca PLC

4.98 81M
Healthcare

UCB SA

4.96 81M
Healthcare

Bristol-Myers Squibb Co

4.61 75M
Healthcare

Roche Holding AG Ordinary Shares new

4.57 75M
Healthcare

Gilead Sciences Inc

4.47 73M
Healthcare

Elanco Animal Health Inc

4.26 70M
Healthcare

Sponsor Center